SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%SPX 6,124.35 ▲ 0.47%DJI 44,210.18 ▼ 0.12%CCMP 19,875.02 ▲ 0.72%SX5E 5,231.77 ▲ 0.24%UKX 8,402.11 ▼ 0.22%NKY 39,870.50 ▲ 0.78%EURUSD 1.0842 ▼ 0.19%USGG10YR 4.31 ▲ 0.94%CL1 71.82 ▼ 0.88%XAU 2,685.40 ▲ 0.42%XBT 97,250.00 ▲ 1.93%
 

← Persons Index

Hasmukh Chudgar & family
Rank #434 · Healthcare

Hasmukh Chudgar & family

Pharmaceuticals · India

Net worth$8.4B
Today+$0
7 days+$800
30 days+$800K

Net worth, last 30 days

Low $8.4BHigh $8.4B

Biography

Low profile Hasmukh Chudgar founded generics maker Intas Pharmaceuticals in 1977.

Chudgar has long handed over operations to his sons Nimish and Binish, who run the $2.9 billion (revenue) company.

In August 2025, Intas Pharma acquired biosimilar Udenyca from California-based Coherus Life Sciences for $558 million.

The company's portfolio includes an affordable drug to treat breast cancer called Eleftha, which is similar to Roche's Herceptin.

In 2022, the Abu Dhabi Investment Authority bought a 3% stake in Intas from Temasek.

Did you know

Chudgar's third son Urmish heads the company's biopharma business and is a haematologist-oncologist.

The company's biggest markets are Europe and India.